Fertility-sparing Management Using High-dose Oral Progestin in Young Women With Endometrial Cancer

• Status: Not yet recruiting
• Trial end date: 2022-11-30
• Target enrollment: 0
• Participant gender: Female

Summary

This registry aims to evaluate the efficacy of using high-dose oral progestin in young women with stage I endometrial adenocarcinoma with grade 2 differentiation or superficial myometrial invasion as a fertility-sparing management.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Asan Medical Center
• Collaborator: Korean Gynecologic Oncology Group
• Treatments: Medroxyprogesterone; Medroxyprogesterone Acetate; Progestins

Criteria

Inclusion Criteria:

• Patients with histologically confirmed grade 1 endometrioid adenocarcinoma with superficial myometrial invasion based on Magnetic resonance image(MRI)

• Patients with histologically confirmed grade 2 endometrioid adenocarcinoma that is presumably confined to the endometrium based on MRI

• Patients with histologically confirmed grade 2 endometrioid adenocarcinoma with superficial myometrial invasion based on MRI

• Patients who desire to preserve fertility potential

• Patients signed the written informed consent voluntarily

Exclusion Criteria:

• Patients who have severe underlying disease or complication

• Under treatment of metastatic cancer from other organs or less than 5 years after previous cancer therapy

• Acute liver disease or kidney disease

• Thrombosis or phlebothrombosis requiring treatment, Hyperlipidemia, Smoker